83 related articles for article (PubMed ID: 27987232)
21. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
22. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
23. Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma.
Liu Y; Poon RT; Feng X; Yu WC; Luk JM; Fan ST
Am J Gastroenterol; 2004 Jun; 99(6):1111-21. PubMed ID: 15180734
[TBL] [Abstract][Full Text] [Related]
24. High expression of herpesvirus entry mediator (HVEM) in ovarian serous adenocarcinoma tissue.
Fang Y; Ye L; Zhang T; He QZ; Zhu JL
J BUON; 2017; 22(1):80-86. PubMed ID: 28365939
[TBL] [Abstract][Full Text] [Related]
25. Expression level of Bcl-XL critically affects sensitivity of hepatocellular carcinoma cells to LIGHT-enhanced and interferon-gamma-induced apoptosis.
Li J; Shen F; Wu D; Wei LX; Wang YZ; Shi LH; Zou Y; Wu MC
Oncol Rep; 2007 May; 17(5):1067-75. PubMed ID: 17390046
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
Han MZ; Wang S; Zhao WB; Ni SL; Yang N; Kong Y; Huang B; Chen AJ; Li XG; Wang J; Wang DH
EBioMedicine; 2019 May; 43():159-170. PubMed ID: 30987862
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
28. Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma.
Wang XD; Wang L; Ji FJ; Zhu JM; Ayana DA; Fang XD
J Int Med Res; 2012; 40(1):307-16. PubMed ID: 22429370
[TBL] [Abstract][Full Text] [Related]
29. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
30. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
[TBL] [Abstract][Full Text] [Related]
31. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
32. Elevated serum soluble CD14 levels in chronic HBV infection are significantly associated with HBV-related hepatocellular carcinoma.
Li N; Zhu Q; Yang C; Li F; Zhou Z; Lv Y; Sang J; Han Q; Liu Z
Tumour Biol; 2016 May; 37(5):6607-17. PubMed ID: 26643893
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
[TBL] [Abstract][Full Text] [Related]
35. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma.
Zhou C; Zhou HJ; Zhang XF; Lou LL; Ye QH; Zheng Y; Wang J; Zhu HT; Dong QZ; Jia HL; Zhu WW; Guo L; Zhao Y; Gao DM; Qin LX
Ann Surg Oncol; 2013 Mar; 20(3):929-37. PubMed ID: 23203407
[TBL] [Abstract][Full Text] [Related]
36. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of serum B7-H4 for hepatocellular carcinoma.
Zhang C; Li Y; Wang Y
J Surg Res; 2015 Aug; 197(2):301-6. PubMed ID: 25963168
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of peripheral blood lymphocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma.
Nakamoto Y; Kaneko S; Buttner SW; Matsushita E; Kobayashi K
Oncol Rep; 1999; 6(4):733-9. PubMed ID: 10373647
[TBL] [Abstract][Full Text] [Related]
39. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
40. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model.
Wang X; Zhang J; Zhou L; Lu P; Zheng ZG; Sun W; Wang JL; Yang XS; Li XL; Xia N; Zhang N; Dou KF
Int J Clin Exp Pathol; 2015; 8(2):1466-78. PubMed ID: 25973032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
